Biosafe, headquartered in Switzerland, is a veteran in the field of bioprocessing, regenerative medicine and stem cell banking.
A GE spokesperson said the company will gain 85 new employees and about 230 customers through the acquisition to double GE’s cell therapy staff and sales, according to a Reuters report.
“GE is building a world-class set of tools, technologies and services for cell and gene therapy and Biosafe’s expertise and innovative systems will strongly enhance our customer offering,” said Kieran Murphy, CEO of Life Sciences for England-based GE Healthcare.
More articles on supply chain:
10 costliest medical conditions
FDA Commissioner: US needs improved system to track medical device issues
This liquid is painted on cavities to stop tooth decay
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
